Shanghai Allist Pharmaceuticals Co. Ltd. A (688578) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of Shanghai Allist Pharmaceuticals Co. Ltd. A stock ¥125, price ¥87.47, upside +43.0%, quality 81 out of 100. Rating: undervalued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 8, 2026.
How to read this chart
60‑month range ¥15.11 – ¥133.00 · fair‑value band ¥73.63 – ¥264.29 · the ¥87.47 price screens below the ¥125.07 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 8, 2026.
Follow Shanghai Allist Pharmaceuticals Co. Ltd. A in your weekly email
Every Wednesday you see whether Shanghai Allist Pharmaceuticals Co. Ltd. A is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Shanghai Allist Pharmaceuticals Co., Ltd., a pharmaceutical company, engages in the research and development of tumor-targeted drugs in China in internationally.
Show moreShow less
The company's lead product is vometinib mesylate tablet for the treatment of patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer (NSCLC). It also develops pralatinib capsules, as well as glerexyl citrate tablets for treating adult patients with locally advanced or metastatic NSCLC. The company was founded in 2004 and is based in Shanghai, China.
Stock analysis
Shanghai Allist Pharmaceuticals Co. Ltd. A (688578) currently trades at ¥87.47, while our model-based Fair Value estimate is ¥125.07, implying the stock looks roughly 30% undervalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of ¥225.21 per share, and 15 of the 26 models we run sit above the ¥87.47 price.
Bear case: the Dividend Discount group reads lowest at ¥13.84, and 11 of the 26 models stay below the price. Data coverage for this calculation is high.
Scenario range: ¥73.63 (bear) to ¥264.29 (bull), the price of ¥87.47 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 81/100 (high quality), in the Healthcare sector.
Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Shanghai Allist Pharmaceuticals Co. Ltd. A reported revenue of 5.2B CNY in FY2025 versus 530M CNY in FY2021, a compound +76.7%/yr. Reported net income was 2.2B CNY in FY2025, compounding +230.5%/yr from FY2021. FY2021 was a trough year, so the rate overstates the trend.
Key figures
Market cap 39.3B CNY (≈ $5.9B) Mid · P/E ratio 14.1 · P/S ratio 6.41 · EPS (TTM) ¥6.19 · Dividend yield 1.4% · Net margin 43.7% · Return on equity 36.7% · Return on assets (EBIT) 15.9% (5-year average).
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 90 out of 100 (medium confidence).
What moves the price
The share trades about 34% below its 52-week high and 13% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at 43%, 688578 screens cheaper than that median.
Fair Value models
Bear¥73.63Fair Value ¥125.07Bull¥264.29
Price ¥87.47 · Upside +43.0%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (¥4.27 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.100/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+45.4%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+87.0%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+520.8%
Start year 2020 (pandemic)
Revenue growth 8 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+125.5%
’17
’18
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−55,350.1% (2020) → 49.7% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: rate outside our plausibility band
not computed
Growth Forecast
Little optimism in the price
The price assumes less growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+4.9%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (China: IMF forecast 1.7% a year to 2030, 1.4% from 2016 to 2025) that is about +3.2% a year for the price.
Compare Shanghai Allist Pharmaceuticals Co. Ltd. A with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 558 stocks
Beats the industry median on 11/13 measures
Overall it ranks above its industry peers.
Valuation
Quality Score81 · Top 25%
Fair Value upside+43.0% · Top 25%
Profitability
Return on equity (12 months)36.7% · Top 25%
Return on assets27.6% · Top 25%
Net margin (12 months)43.7% · Top 25%
Operating margin (12 months)48.4% · Top 25%
Growth and dividend
Revenue growth (quarter YoY)36.1% · Top 25%
Dividend yield (12 months)1.4% · Above median
Valuation Multiplesvs Biotechnology median · lower = cheaper
P/E (12 months)14.1× · Cheapest 25%
P/B6.05× · Priciest 25%
P/S (12 months)6.41× · Pricier than median
Price / free cash flow (fiscal year)18.4× · Cheaper than median
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Shanghai Allist Pharmaceuticals Co. Ltd. A Fair Value". https://www.fairvalue-calculator.com/stock/688578
Frequently asked questions
Is Shanghai Allist Pharmaceuticals Co. Ltd. A (688578) overvalued or undervalued?
As of Nov 8, 2026, our model estimates a fair value of ¥125.07 versus a price of ¥87.47, about +43% upside (undervalued).
What is the fair value of 688578?
Our model-based fair value for Shanghai Allist Pharmaceuticals Co. Ltd. A is ¥125.07 (as of Nov 8, 2026), built from audited fundamentals. The current price: ¥87.47.
What is the quality score of 688578?
Shanghai Allist Pharmaceuticals Co. Ltd. A has a Quality Score of 81/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Shanghai Allist Pharmaceuticals Co. Ltd. A (688578)?
Our model-based price target is the fair value of ¥125.07 (as of Nov 8, 2026) from 26 valuation models. Cautious scenario ¥73.63, optimistic scenario ¥264.29. It is a calculation from audited fundamentals, not an analyst target.
What is the Shanghai Allist Pharmaceuticals Co. Ltd. A stock forecast for 2026?
Our models put fair value at ¥125.07, about +43% upside versus a price of ¥87.47 (undervalued). Cautious scenario ¥73.63, optimistic scenario ¥264.29. The calculation is refreshed regularly with new filings.
What is the revenue of Shanghai Allist Pharmaceuticals Co. Ltd. A (688578)?
Shanghai Allist Pharmaceuticals Co. Ltd. A reported trailing-twelve-month revenue of about 6.1B CNY (latest available figure, as of Nov 8, 2026).
Does Shanghai Allist Pharmaceuticals Co. Ltd. A pay a dividend?
Shanghai Allist Pharmaceuticals Co. Ltd. A currently shows a dividend yield of 1.37% relative to its recent price (as of Nov 8, 2026).
How much is the dividend of Shanghai Allist Pharmaceuticals Co. Ltd. A (688578) and when is the ex-dividend date?
Shanghai Allist Pharmaceuticals Co. Ltd. A pays a dividend of ¥1.20 per share a year, a dividend yield of 1.4%. The last ex-dividend date was Sep 2, 2026. The payout ratio is 19.4% of earnings. Free cash flow covers the dividend 3.96 times. Our assessment: Well covered. A low payout and the dividend is fully funded by free cash flow, a comfortable, sustainable dividend.
What growth is priced into Shanghai Allist Pharmaceuticals Co. Ltd. A (688578)?
For today's price to be fair in a discounted-cash-flow model, Shanghai Allist Pharmaceuticals Co. Ltd. A would have to grow free cash flow by +4.9 % per year for five years (discount rate 9.1 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +520.8 % per year. As of Nov 8, 2026.
What discount rate (WACC) does the fair value of 688578 use?
Our models discount Shanghai Allist Pharmaceuticals Co. Ltd. A at 9.1 %: a base by market capitalisation (mid), damped by beta 0.00, country premium for China. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Shanghai Allist Pharmaceuticals Co. Ltd. A that is +4.9 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (9.1 %) and the same formula as our fair value.
How much growth has Shanghai Allist Pharmaceuticals Co. Ltd. A (688578) delivered so far?
Over the past 5 years revenue at Shanghai Allist Pharmaceuticals Co. Ltd. A grew +520.8 % a year. The price currently implies free-cash-flow growth of +4.9 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Shanghai Allist Pharmaceuticals Co. Ltd. A (688578) growing?
The median revenue growth in the sector is +6.2 % a year. That is the yardstick for the growth priced into Shanghai Allist Pharmaceuticals Co. Ltd. A (+4.9 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Shanghai Allist Pharmaceuticals Co. Ltd. A (688578)?
The free-cash-flow yield on the price is 5.43 %: that much free cash flow Shanghai Allist Pharmaceuticals Co. Ltd. A produces per unit of market value. When it exceeds the discount rate of our models (9.1 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Shanghai Allist Pharmaceuticals Co. Ltd. A (688578)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Shanghai Allist Pharmaceuticals Co. Ltd. A it is ¥125.07 per share (as of Nov 8, 2026), against a price of ¥87.47. It is the blended result of 26 valuation models in 8 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is Shanghai Allist Pharmaceuticals Co. Ltd. A stock overvalued or undervalued in 2026?
As of Nov 8, 2026, 688578 trades below its calculated fair value: price ¥87.47, fair value ¥125.07, a gap of about +43% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 688578?
No. The price is what the market pays today (¥87.47); the fair value is what the company's own numbers justify (¥125.07). For Shanghai Allist Pharmaceuticals Co. Ltd. A the two are ¥37.60 per share apart. That gap is exactly why we show both numbers side by side.
How much is Shanghai Allist Pharmaceuticals Co. Ltd. A worth?
The market values Shanghai Allist Pharmaceuticals Co. Ltd. A at about 39.3B CNY (market capitalisation, as of Nov 8, 2026). Per share that is ¥87.47; our models calculate a fair value of ¥125.07 per share.
What do the bullish and bearish scenarios say about 688578?
Our models span a range for Shanghai Allist Pharmaceuticals Co. Ltd. A: cautious scenario ¥73.63, base ¥125.07, optimistic ¥264.29 per share (as of Nov 8, 2026, price ¥87.47). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 688578?
Shanghai Allist Pharmaceuticals Co. Ltd. A trades at a price-to-earnings ratio of 14.1 (as of Nov 8, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ¥125.07 is built from several models across several years. Median P/E at fiscal year-end, 5 fiscal years (2021 to 2025), reported earnings: 29.1. Other multiples: P/B 6.1, P/S 6.4, EV/EBITDA 14.3.
How solid is the balance sheet of Shanghai Allist Pharmaceuticals Co. Ltd. A (688578)?
Balance-sheet figures for Shanghai Allist Pharmaceuticals Co. Ltd. A (as of Nov 8, 2026): return on equity 36.7%. They feed the Quality Score of 81/100, which measures business quality independently of the share price.
How far is 688578 from its 52-week high?
Shanghai Allist Pharmaceuticals Co. Ltd. A trades at ¥87.47, about 34% below its 52-week high of ¥133.00 and 13% above the low of ¥77.14 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of ¥125.07 is for.
Which stocks are comparable to Shanghai Allist Pharmaceuticals Co. Ltd. A?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, CSL Limited, argenx SE, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Shanghai Allist Pharmaceuticals Co. Ltd. A stock attractive at the current price?
The data as of Nov 8, 2026: price ¥87.47, calculated fair value ¥125.07 (+43%), Quality Score 81/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 688578 calculated?
We run Shanghai Allist Pharmaceuticals Co. Ltd. A through 26 models from 8 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of ¥125.07 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0% above its aggregate fair value. Shanghai Allist Pharmaceuticals Co. Ltd. A currently trades 30% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Shanghai Allist Pharmaceuticals Co. Ltd. A (688578)?
The closing price on Nov 6, 2026 was ¥87.47. Our model-based fair value is ¥125.07, about +43% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Shanghai Allist Pharmaceuticals Co. Ltd. A right now?
The rarer combination: high quality (81/100) AND below fair value. That earns a closer look rather than a quick verdict. The model range is unusually wide (¥73.63 to ¥264.29). The outcome hinges heavily on assumptions, so read the point estimate with caution.
Key figures of Shanghai Allist Pharmaceuticals Co. Ltd. A
How large is the market capitalisation of Shanghai Allist Pharmaceuticals Co. Ltd. A (688578)?
The market capitalisation of Shanghai Allist Pharmaceuticals Co. Ltd. A is 39.3B CNY (≈ $5.9B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Shanghai Allist Pharmaceuticals Co. Ltd. A (688578)?
The price-to-sales ratio of Shanghai Allist Pharmaceuticals Co. Ltd. A is 6.41 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Shanghai Allist Pharmaceuticals Co. Ltd. A (688578)?
Earnings per share at Shanghai Allist Pharmaceuticals Co. Ltd. A are ¥6.19 (price ÷ EPS = P/E 14.1). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Shanghai Allist Pharmaceuticals Co. Ltd. A (688578)?
The dividend yield of Shanghai Allist Pharmaceuticals Co. Ltd. A is 1.4% (payout 19.4%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Shanghai Allist Pharmaceuticals Co. Ltd. A (688578)?
The net margin of Shanghai Allist Pharmaceuticals Co. Ltd. A is 43.7% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Shanghai Allist Pharmaceuticals Co. Ltd. A (688578)?
The return on equity (ROE) of Shanghai Allist Pharmaceuticals Co. Ltd. A is 36.7% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Shanghai Allist Pharmaceuticals Co. Ltd. A (688578)?
On an EBIT basis the return on assets of Shanghai Allist Pharmaceuticals Co. Ltd. A is 15.9% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Shanghai Allist Pharmaceuticals Co. Ltd. A (688578)?
The operating margin of Shanghai Allist Pharmaceuticals Co. Ltd. A is 48.4% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Shanghai Allist Pharmaceuticals Co. Ltd. A (688578)?
Revenue at Shanghai Allist Pharmaceuticals Co. Ltd. A is growing +36.1% versus a year earlier (3y avg +87.0%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Shanghai Allist Pharmaceuticals Co. Ltd. A (688578)?
Earnings per share at Shanghai Allist Pharmaceuticals Co. Ltd. A are growing +40.4% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net cash does Shanghai Allist Pharmaceuticals Co. Ltd. A (688578) hold?
Shanghai Allist Pharmaceuticals Co. Ltd. A holds more cash than debt, 587M CNY net (fiscal year 2024). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Shanghai Allist Pharmaceuticals Co. Ltd. A in the live analysis
One click puts Shanghai Allist Pharmaceuticals Co. Ltd. A on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Broad data
Nov 8, 2026